•
FB
FBIOP
Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
yahooPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
--
Volume
8.27K
52W High
$12.98
52W Low
$4.72
Open
$0.00
Prev Close
$12.20
Day Range
0.00 - 0.00
About Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
Latest News
Fortress Biotech Investigated by the Portnoy Law Firm
GlobeNewswire Inc.•Oct 1
Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101
GlobeNewswire Inc.•Oct 1
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics
Benzinga•May 30
Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference
GlobeNewswire Inc.•May 7
Mustang Bio Announces Closing of $8 Million Public Offering
GlobeNewswire Inc.•Feb 10
Mustang Bio Announces Pricing of $8 Million Public Offering
Benzinga•Feb 6
Mustang Bio Announces Pricing of $8 Million Public Offering
GlobeNewswire Inc.•Feb 6
Fortress Biotech CEO buys $36.7k in preferred stock - Investing.com
Investing.com•Jul 10